Living donor liver transplantation has become an accepted treatment for various terminal liver diseases.
Dr Toru Ikegami and colleagues from Japan reviewed 42 living donor liver transplantations performed for acute liver failure during a 10-year period at Kyushu University Hospital.
|1-year survival rates were 80% for survival in patients|
|Journal of the American College of Surgery|
The researchers found causes of liver failure included Hepatitis B, Hepatitis C, autoimmune hepatitis, Wilson's disease, and unknown causes.
The graft types were left lobe, right lobe, and lateral segment.
The team found the mean graft volume to standard liver volume ratios were 42% in left lobe grafts, and 51% in right lobe grafts.
Extubation was significantly delayed in grade IV encephalopathy patients compared with patients with other grades.
The team found all other patients, except one with a subarachnoid hemorrhage, had complete neurologic recovery after transplantation.
The research team noted that the 1- and 10-year survival rates were 78% and 66%, respectively, for grafts, and 80% and 68%, respectively, for patients.
Dr Ikegami's team concluded, "Outcomes of living donor liver transplantation for acute liver failure are fairly acceptable despite severe general conditions and emergent transplant settings."
"Living donor liver transplantation is now among the currently accepted life-saving treatments of choice for acute liver failure, although innovative medical treatments for this disease entity are still anticipated."